Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Cassava Sciences Inc SAVA

Healthcare
Cassava Sciences, Inc. is a clinical-stage biopharmaceutical company focused on neuroscience. The Company's science is based on stabilizing, but not removing, a critical protein in the Alzheimer’s brain. Its scientific approach for the treatment of Alzheimer's disease seeks to simultaneously suppress both neurodegeneration and neuroinflammation. It has two biopharmaceutical assets under... see more

Recent & Breaking News (NDAQ:SAVA)

SAVA ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of Cassava Sciences, Inc. Shareholders Who Lost Money

Accesswire 3 hours ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Cassava Sciences, Inc. (SAVA) and Encourages Stockholders to Learn More About the Investigation

Accesswire 4 hours ago

Did Cassava Sciences, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - SAVA

Accesswire 6 hours ago

Cassava Sciences Topline Phase 3 Data Did Not Meet Co-Primary Endpoints

GlobeNewswire 13 hours ago

Cassava Sciences to Hold Corporate Update on November 25th

GlobeNewswire 1 day ago

Cassava Sciences Appoints Freda Nassif as Chief Commercial Officer

GlobeNewswire 7 days ago

Cassava Sciences Reports Q3 2024 Financial and Operating Results

GlobeNewswire November 7, 2024

Cassava Sciences to Report Third Quarter 2024 Results on November 7, 2024

GlobeNewswire October 31, 2024

Cassava Sciences Resolves SEC Investigation

GlobeNewswire September 26, 2024

Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials

GlobeNewswire September 24, 2024

Cassava Sciences Names Rick Barry as Chief Executive Officer

GlobeNewswire September 9, 2024

Cassava Sciences to Present at the H.C. Wainwright Global Investment Conference

GlobeNewswire September 3, 2024

Cassava Sciences Reports Q2 2024 Financial Results and Operational Updates

GlobeNewswire August 8, 2024

Cassava Sciences Mourns the Death of Board Member Sanford "Sandy" Robertson

GlobeNewswire August 5, 2024

Cassava Sciences to Hold Conference Call to Discuss Recent Developments and Provide a Company Update on Thursday, August 8, 2024 at 8:30 am ET

GlobeNewswire August 1, 2024

Cassava Sciences Announces Expansion of Open-Label Extension Trials

GlobeNewswire July 30, 2024

Cassava Sciences Announces Changes in Executive Leadership, Enhanced Corporate Governance and Other Initiatives

GlobeNewswire July 17, 2024

Lifshitz Law PLLC Announces Investigations of Maplebear, Inc. (NASDAQ: CART), Cassava Sciences, Inc. (NASDAQ: SAVA), DICK'S Sporting Goods, Inc. (NYSE: DKS), and Lantronix, Inc. (NASDAQ: LTRX)

Accesswire July 2, 2024

Cassava Sciences Issues Statement on Former Science Advisor

GlobeNewswire June 28, 2024

Lifshitz Law PLLC Announces Investigations of Cassava Sciences, Inc. (NASDAQ: SAVA), iRhythm Technologies, Inc. (NASDAQ: IRTC), Xponential Fitness, Inc. (NYSE: XPOF), and Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX)

Accesswire May 31, 2024